Search
Carbopol 974P
go.drugbank.com/drugs/DB05384ApprovedWithdrawnThe compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued. … It was under development by ReProtect LLC. It is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies.
Human Menstrual Blood-derived Stem Cells
go.drugbank.com/drugs/DB15738InvestigationalESCs are from the inner cell mass of blastocysts while ASCs are deposited into adult tissues with restricted differentiation potency but also a lack of tumorigenicity. … Menstrual blood-derived stem cells (MenSCs) are mesenchymal-like ASCs which are non-invasively derived from menstrual blood from the shed endometrium of a human female.
Bortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigational[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.
Synonyms: N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamideBelatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalIt was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Aminocaproic acid
go.drugbank.com/drugs/DB00513ApprovedInvestigationalAn antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
Delamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall [A31965]. … Delamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan).
Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16714ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae* serotype 10A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from
Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16717ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae* serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from
Streptococcus pneumoniae type 23A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19348ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of _Streptococcus pneumoniae_ serotype 23A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from
Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10295ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae* serotype 5 individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from